Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice - PubMed
- ️Tue Jan 01 1991
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
P Soriano et al. Cell. 1991.
Abstract
To understand the normal, physiological role of the c-src proto-oncogene, a null mutation was introduced into the gene by homologous recombination in mouse embryonic stem cells. Two independent targeted clones were used to generate chimeras that transmitted the mutated allele to their offspring. Intercrossing of heterozygotes gave rise to live born homozygotes, but most of these mice died within the first few weeks of birth. Histological and hematological examination of the homozygous mutants did not reveal detectable abnormalities in the brain or platelets, where src is most highly expressed. However, these mutants were deficient in bone remodeling, indicating impaired osteoclast function, and developed osteopetrosis. These results demonstrate that src is not required for general cell viability (possibly because of functional overlap with other tyrosine kinases related to src) and uncover an essential role for src in bone formation.
Similar articles
-
Chackalaparampil I, Peri A, Nemir M, Mckee MD, Lin PH, Mukherjee BB, Mukherjee AB. Chackalaparampil I, et al. Oncogene. 1996 Apr 4;12(7):1457-67. Oncogene. 1996. PMID: 8622862
-
Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. Davis AC, et al. Genes Dev. 1993 Apr;7(4):671-82. doi: 10.1101/gad.7.4.671. Genes Dev. 1993. PMID: 8458579
-
Pleiotropic effects of a null mutation in the c-fos proto-oncogene.
Johnson RS, Spiegelman BM, Papaioannou V. Johnson RS, et al. Cell. 1992 Nov 13;71(4):577-86. doi: 10.1016/0092-8674(92)90592-z. Cell. 1992. PMID: 1423615
-
Production of mouse ES cells homozygous for Cdk5-phosphorylated site mutation in c-Src alleles.
Kato G, Maeda S. Kato G, et al. J Biochem. 2003 May;133(5):563-9. doi: 10.1093/jb/mvg072. J Biochem. 2003. PMID: 12801906
-
The p60c-src family of protein-tyrosine kinases: structure, regulation, and function.
Brickell PM. Brickell PM. Crit Rev Oncog. 1992;3(4):401-46. Crit Rev Oncog. 1992. PMID: 1384720 Review.
Cited by
-
Dustin CM, Habibovic A, Hristova M, Schiffers C, Morris CR, Lin MJ, Bauer RA, Heppner DE, Daphtary N, Aliyeva M, van der Vliet A. Dustin CM, et al. J Immunol. 2021 Jun 15;206(12):2989-2999. doi: 10.4049/jimmunol.2000995. Epub 2021 Jun 4. J Immunol. 2021. PMID: 34088769 Free PMC article.
-
The role of SRC family kinases in prostate cancer.
Tatarov O, Edwards J. Tatarov O, et al. Transl Oncogenomics. 2007 Oct 14;2:67-77. Print 2007. Transl Oncogenomics. 2007. PMID: 23641146 Free PMC article. No abstract available.
-
Ito M, Sugihara K, Asaka T, Toyama T, Yoshihara T, Furuichi K, Wada T, Asano M. Ito M, et al. PLoS One. 2012;7(1):e29873. doi: 10.1371/journal.pone.0029873. Epub 2012 Jan 13. PLoS One. 2012. PMID: 22253810 Free PMC article.
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.
Boyce B, Xing L. Boyce B, et al. Clin Investig (Lond). 2011 Dec 1;1(12):1695-1706. doi: 10.4155/cli.11.150. Clin Investig (Lond). 2011. PMID: 22384312 Free PMC article.
-
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE, Corn PG, Zurita AJ, Lin SH. Gallick GE, et al. Future Med Chem. 2012 Jan;4(1):107-19. doi: 10.4155/fmc.11.161. Future Med Chem. 2012. PMID: 22168167 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous